28
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Final adult height of patients with childhood-onset systemic lupus erythematosus: a cross sectional analysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          To compare final height to mid-parental target height among adults with childhood-onset systemic lupus erythematosus (cSLE) versus adult-onset SLE (aSLE), and to evaluate the impact of age at SLE onset on final height.

          Methods

          Data derived from the Lupus Outcomes Study, a longitudinal cohort of adults with SLE, was used for this cross-sectional analysis ( N = 728). Participants aged 18–63 years with complete height data were included ( N = 566) and were classified as cSLE if age at diagnosis was < 18 years (N = 72). The Tanner formula was used to calculate mid-parental target height. Multivariate linear regression was used to determine mean difference between final height and target height. Multivariate logistic regression was used to compare odds of substantially reduced final height, defined as > 2 SD below target height. Separate analyses were conducted for females and males to account for differences in timing of the pubertal growth spurt for each sex.

          Results

          Participants with cSLE were, on average, 2.4 cm shorter than their target height (95% CI -4, − 0.7). The adjusted odds ratio (OR) for substantially reduced final height was 3.9 (95% CI + 2.0, + 7.2, p < 0.001) as compared to participants with aSLE. Females diagnosed between 11 and 13 years were at greatest risk for substantially reduced final height, with adjusted OR of 11.2 (95% CI + 3.4, + 36.3) as compared to participants with aSLE ( p < 0.001).

          Conclusions

          cSLE is associated with shorter-than-expected final height. Onset of SLE in the pubertal period, near the time of maximum linear growth, may have a particularly significant impact on final height.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Normal growth and techniques of growth assessment.

          J M Tanner (1986)
          The shape of the human growth curve is described and illustrated. Growth studies may be longitudinal, cross-sectional, mixed longitudinal or linked-longitudinal; each has advantages and disadvantages, and each requires appropriate statistical methods for handling the data. Standards for height and height velocity for use in a clinical setting wherein follow-up over several years is presumed are described and illustrated. Such standards have to take into account tempo of growth at ages over nine years. Cross-sectionally derived standards do not do this and are not suitable for clinical use. The techniques of measurement of height, sitting height and skinfolds are described and illustrated. Growth and development during puberty is described; there are changes in body composition as well as in body size and shape. Standards for pubertal stages of breasts, pubic hair and genitalia are given and emphasis is laid on the great variation in both the timing and the duration of these pubertal changes. Measurement of developmental age is discussed. The Greulich-Pyle and Tanner-Whitehouse methods for skeletal age are described. These methods can be used for predicting adult height which is useful both in diagnosis and in following the effects of treatment. In diagnosis the predicted adult height is compared to the range of expected heights in the children of the particular pair of parents concerned (the so-called 'target' range of heights) to see if smallness is simply due to delay. Change in Tanner-Whitehouse predicted height occurs on successful treatment of, for example, growth hormone deficient short stature, and is thus a guide to the success of treatment. Standards are also given for height of children from age two to nine inclusive, with allowance for height of their parents.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Evolutionary perspectives on human height variation.

            Human height is a highly variable trait, both within and between populations, has a high heritability, and influences the manner in which people behave and are treated in society. Although we know much about human height, this information has rarely been brought together in a comprehensive, systematic fashion. Here, we present a synthetic review of the literature on human height from an explicit evolutionary perspective, addressing its phylogenetic history, development, and environmental and genetic influences on growth and stature. In addition to presenting evidence to suggest the past action of natural selection on human height, we also assess the evidence that natural and sexual selection continues to act on height in contemporary populations. Although there is clear evidence to suggest that selection acts on height, mainly through life-history processes but perhaps also directly, it is also apparent that methodological factors reduce the confidence with which such inferences can be drawn, and there remain surprising gaps in our knowledge. The inability to draw firm conclusions about the adaptiveness of such a highly visible and easily measured trait suggests we should show an appropriate degree of caution when dealing with other human traits in evolutionary perspective.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease.

              Growth failure is a recognized complication of pediatric-onset Crohn's disease, but there are few data on final adult height. Our purpose with this work was to determine adult height and the clinical features that influence long-term growth impairment. We retrospectively studied 123 patients with Crohn's disease (65 male and 58 female) who had reached adult height. All of the case subjects were diagnosed before age 16.0 years. Heights were converted to SD scores and univariate analysis performed of factors postulated to influence final height, that is, interval from onset of symptoms to diagnosis, prepubertal onset of symptoms, gender, jejunal disease present at diagnosis, systemic steroid therapy, intestinal surgery, and midparental height SD scores. Significant univariate factors were additional analyzed in regression models. Mean height deficit at diagnosis was -0.50 SD scores, which improved to -0.29 SD scores at final height. Mean final height compared with target height, calculated from parental height, was -2.4 cm (range: -20.0 to 9.0 cm). Nineteen percent of the case subjects achieved a final height >8.0 cm below target height. The length of the interval between symptom onset and diagnosis correlated negatively with height SD scores at diagnosis. Height SD scores at diagnosis were related to final height SD scores, independent of midparental height. The presence of jejunal disease was negatively related to final height. Mean final adult height showed a modest deficit compared with target height, but in one fifth of patients, final height was significantly less than target height. Earlier diagnosis and improved treatment of jejunal disease would be likely to improve final height.
                Bookmark

                Author and article information

                Contributors
                415-476-3600 , meravheshin@gmail.com
                liati_137@yahoo.com
                aimee.hersh@hsc.utah.edu
                evonsche@ucsf.edu
                ed.yelin@ucsf.edu
                laura.trupin@ucsf.edu
                jinoos.yazdany@ucsf.edu
                erica.lawson@ucsf.edu
                Journal
                Pediatr Rheumatol Online J
                Pediatr Rheumatol Online J
                Pediatric Rheumatology Online Journal
                BioMed Central (London )
                1546-0096
                23 April 2018
                23 April 2018
                2018
                : 16
                : 30
                Affiliations
                [1 ]ISNI 0000 0001 2297 6811, GRID grid.266102.1, Division of Pediatric Rheumatology, , University of California San Francisco, Benioff Children’s Hospital, ; 550 16th Street, 5th Floor, San Francisco, CA 94143-0632 USA
                [2 ]ISNI 0000 0001 2297 6811, GRID grid.266102.1, Division of Pediatric Endocrinology, , University of California San Francisco, ; San Francisco, CA USA
                [3 ]ISNI 0000 0001 2193 0096, GRID grid.223827.e, Division of Pediatric Rheumatology, , University of Utah, ; Salt Lake City, UT USA
                [4 ]ISNI 0000 0001 2297 6811, GRID grid.266102.1, Division of Rheumatology, , University of California San Francisco, ; San Francisco, CA USA
                [5 ]ISNI 0000 0001 2297 6811, GRID grid.266102.1, Philip R Lee Institute for Health Policy Studies, , University of California, ; San Francisco, CA USA
                Author information
                http://orcid.org/0000-0002-9488-6476
                Article
                239
                10.1186/s12969-018-0239-8
                5913867
                29688869
                fce44854-8bd3-4e4d-b990-95b2016e2be9
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 17 January 2018
                : 27 March 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000069, National Institute of Arthritis and Musculoskeletal and Skin Diseases;
                Award ID: T32-AR007304
                Award ID: P60 AR-053308
                Award ID: P60 AR-053308
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100010946, School of Medicine, University of California, San Francisco;
                Award ID: NCATS UCSF-CTSI UL1-TR001872
                Funded by: Hellman Fellows Fund
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2018

                Pediatrics
                sle,childhood-onset sle,adult-onset sle,final adult height,mid-parental target height,growth hormone

                Comments

                Comment on this article